上海醫藥(02607.HK)6個品種藥物擬中標全國藥品集中採購
格隆匯8月20日丨上海醫藥(02607.HK)公佈,2020年8月20日,公司旗下上海信誼天平藥業有限公司、上海上藥中西製藥有限公司及常州製藥廠有限公司參加了聯合採購辦公室組織的第三批全國藥品集中採購的投標工作。公司根據《國家食品藥品監督管理總局關於發佈化學藥品註冊分類改革工作方案的公告》(2016年第51號),按化學藥品新註冊分類批准的仿製藥品鹽酸二甲雙胍片(0.25g)、鹽酸氨溴索膠囊(30mg)、布洛芬緩釋膠囊(0.3g)、右佐匹克隆片(3mg)、鹽酸氟西汀膠囊(20mg)及卡託普利片(12.5mg,25mg)擬中標本次集中採購,且公司根據各省市場潛力進行了省份遴選。
除上述品種外,公司旗下上海上藥信誼藥廠有限公司的鹽酸二甲雙胍緩釋片(0.5g)及上藥常藥的氯氮平片(25mg)也參與了本次集採競標,但並未入圍。前述未入圍品種2019年度銷售收入合計7,572萬元,約佔公司2019年度工業銷售收入的0.322%,對公司經營狀況並無重大影響。
上述擬中標的6個品種(7個品規)2019年度銷售收入合計約為人民幣16,231元,約佔公司2019年度工業銷售收入的0.691%。
本次集中採購是國家組織的第三批藥品集中帶量採購,採購週期中,醫療機構將優先使用本次藥品集中採購中選藥品,並確保完成約定採購量。若公司後續簽訂採購合同並實施後,將使得公司在無銷售成本的情況下,進一步擴大相關產品的銷售,提高市場佔有率,提升公司品牌影響力,對公司的未來經營業績具有積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.